Marker Therapeutics Inc MRKR:NASDAQ

RT Quote | NASDAQ | USD
Last | 4:00 PM EST
2.50quote price arrow down-0.06 (-2.34%)
Volume
309,938
52 week range
1.32 - 3.77

...

Loading . . .

KEY STATS

  • Open2.65
  • Day High2.65
  • Day Low2.47
  • Prev Close2.56
  • 52 Week High3.77
  • 52 Week High Date02/09/21
  • 52 Week Low1.32
  • 52 Week Low Date10/30/20
  • Market Cap120.07M
  • Shares Out48.03M
  • 10 Day Average Volume0.32M
  • Dividend-
  • Dividend Yield-
  • Beta1.27
  • 1 Year % Change-8.09

RATIOS/PROFITABILITY

  • EPS (TTM)-0.51
  • P/E (TTM)-4.93
  • Fwd P/E (NTM)-3.65
  • EBITDA (MRQ)-23.827M
  • ROE (MRQ)-54.39%
  • Revenue (MRQ)680,000.00
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-3,436.28%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date03/10/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Marker Therapeutics Inc News

There is no recent news for this security.

Latest MRKR News From Our Partners

February 9, 2021

QUOTE FINDER

Profile

MORE
Marker Therapeutics, Inc., formerly TapImmune Inc., is an immuno-oncology company. The Company specializes in the development of peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer. It is engaged in developing vaccines that target candidate breast cancers, colorectal cancers, ovarian cancers and non-small cell lung cancers. It combines a set of licensed technologies, including peptide antigen technologies and deoxyribonucleic acid (DNA)...
Frederick Wasserman CPA
Chairman
Peter Hoang
President
Anthony Kim
Chief Financial Officer
Michael Loiacono
Chief Financial Officer
Gerald Garrett
Vice President
Address
3200 SOUTHWEST FREEWAY, SUITE 2250
Houston, TX
77027
United States